1-3 of 3
Xiaoshu Dai
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 2B, Open-Label Multicenter Study of Tebapivat (AG-946), a Potent Pyruvate Kinase Activator, in Patients with Anemia Due to Lower-Risk Myelodysplastic Syndromes

Amer M. Zeidan, Mikkael A. Sekeres, Hanny Al-Samkari, Hetty E. Carraway, Amy E. DeZern, Moshe Mittelman, Meredith Little, Vanessa Beynon, Xiaoshu Dai, Sal Sommakia, Jenny M. Despotovic, Parija Patel, Melissa Dibacco, Bruno Fattizzo, Eytan M. Stein, David Sallman, Austin G. Kulasekararaj, Uwe Platzbecker, Pierre Fenaux
Journal: Blood
Blood (2024) 144 (Supplement 1): 6708.
https://doi.org/10.1182/blood-2024-203073
Published: 2024
Journal Articles

Results from a Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tebapivat (AG-946) in Patients with Sickle Cell Disease

Julia Z Xu, Enrico M Novelli, Jean-Antoine Ribeil, Andreas Glenthøj, Srila Gopal, Hanny Al-Samkari, Modupe Idowu, Jenny Despotovic, Spurthi Patil, Xiaoshu Dai, Abdullah Al Masud, Michael Callaghan, Fuad El Rassi
Journal: Blood
Blood (2024) 144 (Supplement 1): 2496.
https://doi.org/10.1182/blood-2024-203509
Published: 2024
Journal Articles

Results from the Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers

Xiaoshu Dai Gurov, Elizabeth Merica, Varsha Iyer, Annie Claeys, Spurthi Patil, Rolandas Urbstonaitis, James Xiao, Michael U. Callaghan
Journal: Blood
Blood (2022) 140 (Supplement 1): 5426–5427.
https://doi.org/10.1182/blood-2022-157719
Published: 2022